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Abstract
The nonselective monovalent cation channel transient receptor
potential melastatin 4 (Trpm4) is transcriptionally upregulated in
neural and vascular cells in animal models of brain infarction. It
associates with sulfonylurea receptor 1 (Sur1) to form Sur1-Trpm4
channels, which have critical roles in cytotoxic edema, cell death,
blood-brain barrier breakdown, and vasogenic edema. We examined
Trpm4 expression in postmortem brain specimens from 15 patients
who died within the first 31 days of the onset of focal cerebral is-
chemia. We found increased Trpm4 protein expression in all cases
using immunohistochemistry; transcriptional upregulation was con-
firmed using in situ hybridization of Trpm4 messenger RNA. Tran-
sient receptor potential melastatin 4 colocalized and coassociated
with Sur1 within ischemic endothelial cells and neurons. Coexpression
of Sur1 and Trpm4 in necrotic endothelial cells was also associated
with vasogenic edema indicated by upregulated perivascular tumor
necrosis factor, extravasation of serum immunoglobulin G, and asso-
ciated inflammation. Upregulated Trpm4 protein was present up to
1 month after the onset of cerebral ischemia. In a rat model of middle
cerebral artery occlusion stroke, pharmacologic channel blockade by
glibenclamide, a selective inhibitor of sulfonylurea receptor, mitigated
perivascular tumor necrosis factor labeling. Thus, upregulated Sur1-
Trpm4 channels and associated blood-brain barrier disruption and ce-
rebral edema suggest that pharmacologic targeting of this channel may
represent a promising therapeutic strategy for the clinical management
of patients with cerebral ischemia.
Key Words: Cerebral edema, Cerebral infarct, Endothelium, Neuron,
Neutrophil, Sulfonylurea receptor 1 (Sur1), Transient receptor potential
melastatin 4 (Trpm4).
INTRODUCTION
Cerebral infarcts account for 5.5 million deaths world-
wide each year and are a leading cause of long-term disability
(1Y3). Despite tremendous progress in our understanding of
the pathophysiology of strokes, ongoing efforts to identify
novel molecular targets have yet to yield new therapies. Re-
combinant tissue plasminogen activator remains the only
medication specifically approved by national regulatory agen-
cies for use in patients with ischemic stroke; however, for a
variety of reasons, it is used in less than 20% of stroke victims
(4Y7). Moreover, its use is associated with an increased risk of
intracranial hemorrhage (8). Despite the devastating effects
of malignant cerebral edema on large territorial infarcts, the
only pharmacotherapeutic option for this complication is osmo-
therapy, the effects of which remain unproven. There remains a
critical need to improve our understanding of the molecular
pathogenesis of this devastating neurologic condition to iden-
tify more effective therapeutic strategies.
Transient receptor potential melastatin 4 (Trpm4) is a
member of a large protein superfamily consisting of 28
mammalian cation channels (9,10). Most members of the Trp
family are permeable to divalent cations. The exceptionsV
Trpm4 and Trpm5Vare Ca2+-impermeable channels that
transport monovalent cations exclusively and nonselectively
(9,10). Transient receptor potential melastatin 4 channels are
activated by an increase in cytosolic Ca2+ or by a decrease in
cytosolic ATP (11). Accumulating data show that there is
upregulation of Trpm4 in microvascular endothelial cells,
neurons, and glia in experimental rat models of stroke, spinal
cord injury, and subarachnoid hemorrhage (12Y15). Emerging
evidence suggests that Trpm4 interacts with sulfonylurea re-
ceptor 1 (Sur1) to form a novel ion channel, the Sur1-Trpm4
channel (15), which functions critically in the pathophysiol-
ogy of various acute CNS injuries. Sulfonylurea receptor
1YTrpm4 channels contribute to cytotoxic edema, serve as
end-executioners in accidental necrotic death induced by ATP
depletion or reactive oxygen species (16), and participate in
blood-brain barrier breakdown and formation of ionic and
vasogenic edema (14,17).
Expression of Trpm4 has been investigated in tissue
specimens obtained from patients with multiple sclerosis (18)
and subarachnoid hemorrhage (14), but it has not yet been
studied in human cerebral infarcts. Here, we sought to deter-
mine whether upregulation of Trpm4 protein and messenger
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RNA (mRNA) is present in infarcted human cerebral cortex
and whether Trpm4 protein coassociates with Sur1 to form
Sur1-Trpm4 channels in focal cerebral ischemia in humans,
and we tested the effects of a selective inhibitor of sulfonyl-
urea receptor on an animal model of acute cerebral ischemia.
MATERIALS AND METHODS
Human Tissues
The tissue collection protocol was approved by the In-
stitutional Review Board of the University of Maryland
(Baltimore, MD). Patients who died within 31 days of cerebral
ischemia documented between January 2010 and December
2012 and who underwent autopsy were identified retrospec-
tively by reviewing the records of the Department of Pathology
at the University of Maryland School of Medicine. Within these
constraints, 15 focal cerebral infarcts originating from 13 pa-
tients were identified. For comparison, contralateral cortex
samples were evaluated as control tissue. Brain specimens from
6 patients with documented absence of ischemic lesions also
were examined as controls. For additional validation of anti-
bodies, sections of normal colon surgically removed from
2 patients during bypass surgery were also evaluated. Standard
tissue fixation protocols (7Y10 days in formalin) were applied.
Histologic validation of the presence or absence of an
ischemic lesion in brain specimens was performed by a neu-
ropathologist in all cases. Representative paraffin-embedded
tissue blocks were selected from each case for detailed eval-
uation. For normal brains, blocks encompassing representa-
tive frontal or parietal cortices were studied. Blocks were
sectioned at 6 Km and stained with hematoxylin and eosin or
prepared for immunohistochemistry.
Rat Model of Middle Cerebral Artery Occlusion
Animal experiments were performed following a pro-
tocol approved by the Institutional Animal Care and Use
Committee of the University of Maryland. All experiments
were performed in accordance with relevant guidelines and
regulations in the US National Institutes of Health Guide for the
Care and Use of Laboratory Animals. All efforts were made to
minimize the number of animals used and their suffering.
Male Wistar rats (275Y325 g; Harlan, Indianapolis, IN)
were anesthesized (ketamine 60 mg/kg and xylazine 7.5 mg/kg
intraperitoneally). Peripheral capillary oxygen saturation (SpO2)
via pulse oximetry and temperature were carefully regulated,
and all surgical procedures were performed aseptically. Middle
cerebral artery occlusion (MCAo) was achieved using an in-
traluminal thread. A midline incision was made to expose the
right common carotid artery, external carotid artery, and inter-
nal carotid artery. A 4-0 monofilament nylon suture with a
rounded tip approximately 0.26 mm in diameter was inserted
via the external carotid artery into the internal carotid artery
and was advanced by approximately 18 mm to occlude the
middle cerebral artery, as monitored by Doppler flowmetry.
After 120 minutes, the occluder was removed to allow reper-
fusion. The external carotid artery stump was ligated, and the
neck incision was closed. Using an automatic homeothermic
blanket control unit, we maintained animal body temperature
at 37-C throughout the procedure and during postsurgical
recovery. After the procedure, 12 rats were randomly assigned
to vehicle treatment (n = 6) or glibenclamide treatment (n = 6).
At 48 hours, the animals were killed and their brains were
analyzed for tumor necrosis factor (TNF) expression.
Glibenclamide Treatment
Drug formulation of glibenclamide (number G2539;
Sigma, St Louis, MO) in dimethyl sulfoxide and preparation
of miniosmotic pumps were performed as previously described
(19). Treatment consisted of intraperitoneal administration of a
single loading dose of glibenclamide (10 Kg/kg) or an equiv-
alent volume of vehicle within 10 minutes of ischemia and
continuous infusion (1.0 KL/hour) via miniosmotic pumps
(Alzet 2001; Alzet Corp, Cupertino, CA) beginning at the end
of surgery, resulting in delivery of 200 ng/hour or an equiv-
alent volume of vehicle subcutaneously for 1 week. The dose
of glibenclamide used does not result in hypoglycemia (17).
Antibodies
The custom anti-Trpm4 and anti-Sur1 antibodies used
have been previously described (15). The antigenic peptide
for Trpm4 was the N-terminal intracellular domain of mouse
Trpm4, corresponding to amino acids 1 to 612 (NP 780339).
Anti-Trpm4 antibodies were raised in chicken and used at
1:200 dilution. The antigenic peptide for Sur1 was the intracel-
lular nucleotide-binding domain 1 of Sur1 (rat Sur1 comple-
mentary DNA amino acids 598Y965 of NP 037171). Anti-Sur1
antibodies were raised in rabbit and used at 1:200 dilution.
Other primary antibodies included the following: rabbit antiY
cytokeratin 20 (prediluted; Ventana, Tucson, AZ) for colonic
epithelial cells; mouse antiYglial fibrillary acidic protein (GFAP)
(1:500, CY3-conjugated, C-9205; Sigma) for astrocytes; mouse
anti-NeuN (1:100, MAB377; Chemicon, Temecula, CA) for
neurons; goat anti-CD31 (PECAM-1) (1:200, sc-1506; Santa
Cruz Biotechnology, Santa Cruz, CA) for endothelial cells; goat
antiYimmunoglobulin G (IgG) (1:500, fluorescein isothiocya-
nate [FITC]Yconjugated, NB7477; Novus Biologicals, Littleton,
CO) for IgG; goat anti-TNF (1:100, sc-1350; Santa Cruz
Biotechnology) for TNF; rabbit anti-myeloperoxidase (1:200,
A0398; Dako, Carpinteria, CA) for neutrophils; and mouse
antiYrat endothelial cell antigen 1 (1:100, MA1-81510; Thermo
Fisher, Rockford, IL) for rat endothelium.
Immunohistochemistry and Fo¨rster Resonance
Energy Transfer
Deparaffinized sections were rinsed in ethanol and
washed with phosphate-buffered saline (PBS; 10 mmol/L,
pH 7.4). For antigen retrieval, slides were placed in citrate buffer
(10 mmol/L, pH 8.0), heated in a microwave oven at 900 W
for 10 minutes, and washed in PBS. Slides were incubated
with a mixture of 5% goat serum (Sigma) and 0.2% Triton X-
100 for 1 hour at room temperature before overnight in-
cubation at 4-C with anti-Trpm4 and/or anti-Sur1 antibodies
and, in some cases, with a cell-specific or anti-IgG primary
antibody. Slides were rinsed again in PBS. Single-label im-
munohistochemistry for Trpm4 was developed using biotin-
conjugated secondary antibody. Sections were incubated in
PBS with 0.3% H2O2 for 30 minutes to block endogenous
peroxidase activity. After overnight incubation with primary
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antibody, sections were incubated with biotinylated secondary
antibody (1:500, BA-1000, goat anti-chicken; Vector Labo-
ratories, Burlingame, CA) for 2 hours. After washing in PBS,
sections were incubated in avidin biotin solution (Vector
Laboratories), and color was developed in diaminobenzidine
chromogen solution (0.02% diaminobenzidine in sodium ac-
etate 0.175 mol/L) activated with 0.01% hydrogen peroxide.
Cresyl violet was used as counterstain to visualize cell nuclei.
Sections were rinsed, mounted, dehydrated, and coverslipped
with DPX mounting medium (Electron Microscopy Services,
Fort Washington, PA). Omission of primary antibodies was
used as negative control.
To show localization of Trpm4 and/or Sur1 within
identified cell types and/or coexpression with IgG, we per-
formed immunofluorescence microscopy of anti-Trpm4 or
anti-Sur1 antibodies in addition to cell-specific and anti-IgG
primary antibodies using the standard protocol, as described
previously. Slides were incubated for 1 hour with fluorescence-
labeled species-appropriate secondary antibodies (1:500, Alexa
Fluor 488 and Alexa Fluor 555; Invitrogen/Molecular Probes,
Eugene, OR) at room temperature. Omission of primary antibody
was used as negative control. Sections were coverslipped with
polar mounting medium containing anti-fade reagent and 4¶,6-
diamidino-2-phenylindole (DAPI; Invitrogen). Immunolabeled
sections were visualized using epifluorescence microscopy
(Nikon Eclipse 90i; Nikon Instruments Inc, Melville, NY).
Antibody-based Fo¨rster resonance energy transfer (FRET)
was performed on acute lesions (Cases 1Y4) using anti-Sur1 and
anti-Trpm4 antibodies, as described (14,15), except that FRET
imaging and measurements of FRET efficiency were performed
using a Zeiss LSM710 confocal microscope.
Analysis of Trpm4, Sur1, IgG, and TNF
Protein Expression
Transient receptor potential melastatin 4 immunoreac-
tivity was analyzed for each cell typeYspecific marker for each
case (Table). All sections were immunolabeled as a single
batch, and all images were collected using uniform parame-
ters of magnification and exposure, as previously described
(20,21). Two areas encompassing ischemic lesions or controls
were randomly selected for construction of a montage, with
each montage composed of 16 images (each 300  400 Km)
acquired at 20 magnification. Images were independently
evaluated by 2 observers who were blinded to demographic
and clinical data. Specific Trpm4 immunoreactivity associated
with each cell typeYspecific marker for each case was evalu-
ated. Areas of maximal labeling were scored for each case
using a semiquantitative scale ranging from 0 to 4 as follows:
0, none; 1 (+), weak punctuate labeling present in rare cells
(G10%); 2 (++), weak punctate staining in scattered cells or
aggregates (G50%); 3 (+++) strong punctate staining present
in many cells (950%); 4 (++++) strong diffuse staining of
most cells (990%). The overall concordance between the 2
observers was more than 90%. In cases of disagreement, in-
dependent re-evaluation was performed by both observers to
arrive at the final score. Sulfonylurea receptor 1 immunore-
activity for each cell typeYspecific marker for each case had
been previously reported (22).
Unbiased measurements of specific IgG or TNF label-
ing within regions of interest were obtained, using NIS-
Elements AR software (Nikon Instruments), from sections of
acute lesions (Cases 1Y4) and controls immunolabeled in a
single batch, as previously described (23). All region-of-
interest images for a given signal were captured using uniform
parameters of magnification, area, exposure, and gain. To
quantify IgG or TNF, we defined a circular region of interest
as a perimeter encompassing vessels (with a diameter twice
that of the vessels) within the infarct or control brain. For each
region of interest, a histogram of pixel intensity was con-
structed to determine the intensity of background labeling.
Pixels within the region of interest were defined as having
specific labeling if their intensity was more than 3 times that
of background. The area occupied by pixels with specific la-
beling was used to calculate the percentage of the region of
interest with specific labeling.
In Situ Hybridization of Trpm4 mRNA
Digoxigenin (DIG)Ylabeled probes (antisense, 5¶-
CCGAGAGTGGAATTCCCGGATGAGGCGGTAACGCT
GC-3¶; sense, 5¶-GCAGCGTTACCGCCTCATCCGGGAAT
TCCACTCTCGG-3¶), designed to hybridize nucleotides 3288
to 3324 located within the coding sequence of the human
Trpm4 gene (NM 017636), were supplied by Integrated DNA
Technologies Inc (Coralville, IA). In situ hybridization was
performed on 10-Km-thick sections of acute lesions (Cases
1Y4) and controls using an IsHyb In Situ Hybridization Kit
(Biochain Institute Inc, Newark, CA), according to the man-
ufacturer’s protocol. Deparaffinization and rehydration were
performed as described previously. Sections were incubated
in diethyl pyrocarbonate (DEPC)Ytreated PBS and fixed in
4% paraformaldehyde in PBS for 20 minutes. After being
rinsed twice with DEPC-PBS, slides were treated with pro-
teinase K 10 Kg/mL at 37-C for 10 minutes. Slides were
washed in DEPC-PBS, rinsed with DEPC-H2O, and prehy-
bridized with ready-to-use prehybridization solution (BioChain
Institute Inc) for 3 hours at 50-C. The DIG-labeled probe was
diluted in hybridization buffer (BioChain Institute Inc) and ap-
plied at 4 ng/KL. Sections were incubated at 45-C for 16 hours.
Posthybridization washing and immunologic detection, using
anti-DIG alkaline phosphatase with nitro blue tetrazolium/5-
bromo-4-chloro-3-indolyl-phosphate as substrate, were performed
as recommended by the manufacturer. Alkaline phosphataseY
conjugated anti-DIG antibodies (1:100, PBS-diluted; BioChain
Institute Inc) were incubated on slides for 2 hours. Finally,
slides were rinsed in distilled H2O and immunolabeled for
Trpm4 protein using a fluorescent secondary antibody, as de-
scribed previously. The dark-purple reaction product represents
Trpm4 mRNA; green fluorescence indicates immunohisto-
chemical staining for Trpm4 protein. In situ hybridization of
Sur1 has been previously reported (22).
Statistical Analysis
Two-tailed Fisher exact test was used to determine the
contingency of absent or weak (0/+/++) versus prominent or
diffuse (+++/++++) Trpm4 staining in different cell types
present within infarcted and noninfarcted cortices. Scores for
Trpm4 expression in different cell types were additionally
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analyzed as a function of postmortem and postinfarct intervals
by calculating Spearman correlation coefficient. Both IgG
labeling and TNF labeling were analyzed using Student t-test.
Calculations were performed using OriginPro version 8 (Ori-
gin Lab Corp, Northampton, MA).
RESULTS
Positive and Negative Controls
The custom anti-Trpm4 antibody used here had been
validated previously in rat and human cerebral tissues (14,15).
The specificity of the antibody batch used for this study was
further validated in human colon epithelium, which is known
to express high levels of Trpm4 (Fig. 1) (24). Omission of
primary antibody and tissues obtained from Trpm4 knockout
mice were used as negative controls and confirmed the spec-
ificity of labeling (data not shown).
Trpm4 Expression in Infarcted Cerebral Cortex
Ischemic lesions originated from 15 men and 5 women,
with age at death ranging from 32 to 84 years (mean, 61 years)
(Table). Normal specimens originated from 4 men and 2 women
who had died rapidly of nonneurologic diseases (i.e. acute
cardiovascular or respiratory disorders). Postmortem interval
ranged between 12 and 80 hours. Additional demographic data
on these patients have been reported (22).
TABLE. Trpm4 Protein Expression in Brain Tissue Samples
Case No. Capillaries Venules Arterioles Neurons Astrocytes Neutrophils Postinfarct Interval (days)
Focal ischemic infarcts
1 +++ ++ +++ ++++ ++ +++ 1
2 ++ ++ +++ +++ ++ +++ 3
3 ++++ ++ +++ +++ ++ +++ 5
4 ++ ++ ++ +++ ++ ++++ 5
5 ++++ +++ ++++ +++ ++ ++++ 7
6 ++++ +++ ++++ +++ ++ ++++ 7
7a +++ ++ +++ +++ ++ +++ 7
7b +++ ++ +++ +++ ++ ++++ 7
8 ++ +++ ++ +++ ++ +++ 15
9 ++++ ++++ ++++ ++ +++ ++++ 15
10 ++ +++ ++++ +++ ++++ ++++ 16
11 ++ +++ ++++ ++ ++++ ++++ 26
12 +++ ++++ ++++ ++ ++++ +++ 30
13a +++ ++ +++ ++ +++ +++ 31
13b ++ ++ ++ ++ ++++ ++++ 31
Contralateral
1 + 0 + + ++ 0 1
2 0 0 0 + ++ + 3
3 + 0 + + ++ 0 5
4 0 0 + 0 + 0 5
5 + 0 + + ++ + 7
6 0 0 0 0 0 + 7
7a 0 0 + + ++ ++ 7
7b + 0 + ++ 0 + 7
8 + 0 0 ++ ++ 0 15
9 0 0 0 0 + + 15
10 + 0 + + ++ 0 16
11 0 0 + + + + 26
12 0 + + 0 + ++ 30
13a 0 0 ++ + ++ + 31
13b 0 0 + + ++ + 31
Control brains
14 0 0 0 0 0 0 N/A
15 0 0 0 0 0 + N/A
16 + 0 0 + + 0 N/A
17 0 0 0 0 0 0 N/A
18 0 0 + 0 + + N/A
19 + 0 + + + 0 N/A
Semiquantitative scores are as follows: 0, none; (+) weak punctuate labeling present in rare cells (G10%); (++) weak punctate staining in scattered cells or aggregates
(G50%); (+++) strong punctate staining in many cells (950%); (++++) strong diffuse staining in most cells (990%).
N/A, not applicable.
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Transient receptor potential melastatin 4 protein ex-
pression in infarcted and noninfarcted cortices was analyzed
using immunohistochemistry. Representative sections of acute
infarcts are shown in Figure 2. Immunoperoxidase prepara-
tions revealed prominent Trpm4 immunoreactivity in virtually
all neural and vascular cells (Table; Fig. 2A), whereas non-
infarcted contralateral and control cortices demonstrated only
weak immunoreactivity in rare cells and/or background neuropil
(Table; Fig. 2B).
Immunofluorescent preparations further demonstrated
marked upregulation of Trpm4 in neural and vascular cells in
ischemic infarcts (Figs. 2C, E, G, I, K). Endothelial cells of
capillaries, arterioles, and venules exhibited diffuse membra-
nous and cytoplasmic expression and colabeled for the en-
dothelial cell marker PECAM-1 (CD31) (Figs. 2C, E, G).
Transient receptor potential melastatin 4 immunolabeling also
was prominent in neurons immunoreactive to NeuN (Fig. 2I)
and in astrocytes immunoreactive to GFAP (Fig. 2K). Neu-
rons, endothelial cells, and astrocytes in noninfarcted contra-
lateral and control cortices exhibited weak or no Trpm4
labeling (Table; Figs. 2D, F, H, J, L).
In situ hybridization studies showed de novo transcrip-
tional upregulation of Trpm4 mRNA in acute lesions. We
observed strong labeling of cortical endothelial cells of cap-
illaries, arterioles, and venules, and upregulation in neurons
(Fig. 3, middle column) within ischemic cortices. In situ hy-
bridization signals for Trpm4 mRNA were present in cells
that were strongly immunopositive for Trpm4 protein (Fig. 3,
left column), whereas contralateral and control cortices showed
only faint in situ labeling in rare cells (Fig. 3, right column).
FIGURE 1. Positive controls for Trpm4 immunohistochemistry. (A) Hematoxylin and eosinYstained section of normal colon shows
villus epithelial cells. Immunohistochemistry with primary antibodies against Trpm4 protein shows cytoplasmic labeling of colonic
epithelial cells (B) and colocalization with cytokeratin 20 (CK20) (C). Merged fluorescent image is shown in (D). Scale bar = 50 Km.
Green/FITC, Trpm4; red/CY3, CK20; blue/DAPI.
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FIGURE 3. In situ hybridization shows upregulated Trpm4 mRNA in acute ischemic infarcts. Tissues from recently infarcted cortex
are hybridized with antisense probe and labeled with immunohistochemical stain directed against Trpm4 protein; dual labeling for
Trpm4 mRNA and Trpm4 protein is identified within endothelial cells in capillaries (A), arterioles (C), and venules (E), and in
scattered neurons (G) in ischemic tissues (A, C, E, G) versus contralateral cortex (B, D, F, H). Original magnification: 20. Scale
bar = 10 Km. Images shown are from Cases 3 and 6.
FIGURE 2. Protein Trpm4 is upregulated in focal cerebral infarcts. Low-power images of immunohistochemistry with
diaminobenzidine chromogen staining showing upregulation of Trpm4 in neural and vascular cells of infarcted cortex (A) in
comparison with control (B). With fluorescent double labeling, increased Trpm4 protein is observed within CD31-positive capil-
laries (C), arterioles (E), and venules (G), and within NeuN-positive neurons (I) and GFAP-positive astrocytes (K) in ischemic
tissues (C, E, G, I, K) versus contralateral control tissue samples (D, F, H, J, L). Merged images of double labeling are shown in the
third and fourth columns. Original magnification: 20 (A, B) or 40 (CYN). Scale bars = (A) 100 Km; (C, E, G, I, K, M) 10 Km.
Green/FITC, Trpm4; red/CY3, PECAM-1 (CD31), NeuN, or GFAP; blue/DAPI. Images shown are from Cases 3 and 6.
J Neuropathol Exp Neurol  Volume 74, Number 8, August 2015 Sur1-Trpm4 Channel in Human Cerebral Infarcts
 2015 American Association of Neuropathologists, Inc. 841
Copyright © 2015 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
Time Course of Trpm4 Expression in
Ischemic Cells
Transient receptor potential melastatin 4 expression in
different cell types was evaluated semiquantitatively at vari-
ous times after the onset of ischemic events. There were no
significant differences in any cell type as a function of post-
mortem interval, but upregulated protein was found in neural
and vascular cells as early as 1 day after the clinical onset of
ischemia; it remained elevated in specimens obtained from
patients who died up to 30 days after the clinical onset of
FIGURE 4. Unique pattern of Trpm4 immunoreactivity in astrocytes. Astrocytes show perinuclear dot-like immunoreactivity for
Trpm4 in normal cortex (A), with prominent perinuclear accentuation in acute infarcts (B) and intensified cytoplasmic and distal
process staining in subacute infarcts (C, D). Original magnification: 20. Scale bar = 10 Km. Green/FITC, Trpm4; red/CY3, GFAP;
nuclei stained with DAPI. Merged images shown are from Cases 19, 1, 9, and 13b.
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FIGURE 5. Proteins Trpm4 and Sur1 are upregulated and colocalized in acute ischemic infarcts. Fluorescent double-labeling studies
demonstrate prominent expression in scattered neural and vascular cells of an acute infarct (A) relative to contralateral brain (B).
High-power images of infarcted cortex show colocalization of proteins within capillaries (C), arterioles (E), venules and neutrophils
(G), and within neurons (I) present within infarcted cortex. There is negligible staining in controls (D, F, H, J). Original magnifi-
cation: 20. Scale bar = 10 Km. Green/FITC, Trpm4; red/CY3, Sur1; blue, DAPI. Images shown are from Cases 2 and 3.
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stroke. Significant differences in staining intensities were
found in all cell types, relative to controls (p G 0.05 for as-
trocytes; p G 0.01 for endothelial cells, neurons, and neutro-
phils) (Table). Neurons stained prominently in acute lesions,
with mild regression of staining noted with postinfarct interval
(p G 0.01) (Table). Endothelial cells and neutrophils exhibited
sustained Trpm4 upregulation across time (Table). Astrocytes
exhibited a unique pattern of Trpm4 immunoreactivity: In
noninfarcted cortex, Trpm4 appeared as punctate perinuclear
staining, whereas a progressive increase in the extent of cy-
toplasmic and membranous immunopositivity was observed
with postinfarct interval (p G 0.01) (Table; Fig. 4).
Trpm4 and Sur1 Proteins Are Coexpressed
and Coassociated
Sulfonylurea receptor 1 was previously reported to be
upregulated in endothelial cells, neurons, and astrocytes in
infarcted cerebral cortices (22). Here, we found that upreg-
ulated Trpm4 colocalized with Sur1 in endothelial cells, neu-
rons, and astrocytes in infarcted cerebral cortices (Fig. 5). We
used FRET to determine whether colocalized proteins also
coassociated. Fo¨rster resonance energy transfer analysis dem-
onstrated that Sur1 and Trpm4 coassociated in endothelial cells
(Figs. 6AYD) and neurons. Fo¨rster resonance energy transfer
efficiency, which reflects the proximity of 2 fluorophores, was
13% in infarcted cortices and 0% in controls (Fig. 6E).
Pathologic Correlates of Sur1-Trpm4 Channel
Upregulation in Cerebral Infarcts
Sulfonylurea receptor 1Ypositive/Trpm4-positive endo-
thelial cells and Sur1-positive/Trpm4-positive neurons pres-
ent in infarcted cerebral cortex and peri-infarct zones showed
prominent membrane irregularities and frank blebbing, con-
sistent with cytotoxic edema (Fig. 7A). Coexpression of Sur1
and Trpm4 in abnormal-appearing endothelial cells also was
associated with vasogenic edema, as evidenced by upregu-
lated perivascular labeling for IgG (Figs. 7BYG), TNF (Fig. 7I),
and myeloperoxidase (Fig. 7J). Membrane blebbing was not
identified in Trpm4-negative neural or vascular cells. In addi-
tion, membrane blebbing was not seen in Trpm4-negative or
Trpm4-positive astrocytes present in infarcted or noninfarcted
cortices (Fig. 4).
Inhibition of Sur1 in a Rat Model of MCAo Stroke
To assess the consequences of Sur1-Trpm4 channel
expression, we evaluated the effects of pharmacologic inhi-
bition of Sur1 with glibenclamide in a rat model of MCAo
stroke. Extravasation of serum proteins is known to promote
neuroinflammation. Inhibition of Sur1 was found to mitigate
expression of TNF, an acute-phase reactant cytokine (Fig. 8),
suggesting a critical proinflammatory role for Sur1-Trpm4
channel expression in focal cerebral ischemia.
DISCUSSION
This is the first report to systematically analyze Trpm4
expression in adult human brains after the onset of focal ce-
rebral ischemia. Our findings indicate that Trpm4 mRNA
and Trpm4 protein are upregulated in infarcted human cortex.
The current study is in accordance with a report of Trpm4
upregulation in a preclinical model of stroke (13). In contrast
to the findings in the animal model, however, our study
showed that Trpm4 upregulation was sustained in infarcted
human tissues during acute and subacute postischemic in-
tervals. Analysis of Trpm4 expression in human neurologic
disease was previously limited to specimens originating from
patients with multiple sclerosis (18) or subarachnoid hemor-
rhage (14). Significant upregulation of Trpm4 was identified
under both neuropathologic conditions. In animal models,
Trpm4 expression has been associated with inflammation-
induced axonal and neuronal injuries in demyelinating lesions
(18). Furthermore, endothelial cell upregulation of Trpm4 has
been associated with inflammation and blood-brain barrier
permeability in a model of subarachnoid hemorrhage (14),
and with capillary fragmentation and secondary hemorrhage
in a model of spinal cord injury (12). Together, these studies
suggest a critical function for Trpm4 in acute CNS injuries of
varying etiology.
In a prior analysis, we showed prominent upregulation
of Sur1 (a member of the ATP-binding cassette protein
superfamily) in neural and vascular cells of these same post-
mortem infarct specimens (22). The current study comple-
ments our prior findings and is the first to report that Trpm4,
a voltage-dependent cation channel, colocalizes with Sur1 in
neurons, endothelial cells, astrocytes, and neutrophils present
in human cerebral infarcts. Furthermore, this is the first study
to document, via antibody-based FRET, the coassociation
of upregulated Trpm4 and Sur1 in human cerebral infarcts.
Together, the findings indicate that Sur1-Trpm4 channels
(formerly known as Sur1-regulated NCCa-ATP channels) are
present in infarcted human cerebral cortex, but not in non-
infarcted control specimens.
The Sur1-Trpm4 cation channel is not constitutively
present in CNS tissues but is transcriptionally upregulated de
novo under neuropathologic conditions. Recent data showed
stable heteromultimeric assembly of Sur1 and Trpm4 and
demonstrated that Sur1 regulates the calcium sensitivity of
Trpm4, the pore-forming subunit of the Sur1-Trpm4 channel
FIGURE 6. Proteins Trpm4 and Sur1 coassociate in acute ischemic infarcts. Immunolabeled sections reveal coexpression of Trpm4
and Sur1, with FRET signals elicited in cortical arterioles (A), venules (B), and capillaries (C) in ischemic infarcts. (D) Validation of
antibodies (Abs) for Ab-based FRET analysis. COS-7 cells expressing either Trpm4 or Sur1 (top) or coexpressing both (bottom) were
incubated with either anti-Sur1 or anti-Trpm4 Abs (top) or both (bottom), followed by anti-rabbit Cy3-conjugated plus anti-goat
Cy5-conjugated secondary Abs. Fluorescence images of the 2 fluorophores (left and middle columns) and FRET images (right
column) are shown. Data are representative of 6 replicates. Note that the primary Abs against Sur1 and Trpm4 do not cross-react.
(E) Fo¨rster resonance energy transfer efficiencies in positive controls (PCTR), negative controls (NCTR), and infarcts (Stroke). Scale
bar = 10 Km.
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(15). The channel is activated by a rise in intracellular Ca2+ or
by depletion of intracellular ATP. Channel activation induces
monovalent cation influx that results in cell membrane depo-
larization.
Ca2+ is an important second messenger, and significant
amounts of energy are expended to maintain intracellular
concentrations of free Ca2+ at physiologic levels (È10,000-fold
lower than extracellular levels). Because a large electrochemi-
cal driving force promotes Ca2+ influx into cells, homeostasis
requires Ca2+ extrusion, which is achieved through the plasma
membrane Ca2+-ATPase pump, the Na+-Ca2+ exchanger, and
other energy-dependent mechanisms. Oxygen, glucose, and
energy restriction during cerebral ischemia rapidly results in
increased cytoplasmic Ca2+ (25). If unchecked, excess Ca2+
can lead to enhanced phospholipase and protease activities,
inducing irreversible catabolic processes and producing free
radicals that activate multiple cell death pathways. Thus, there
is an important adaptive advantage in upregulating the ex-
pression of Sur1-Trpm4 (i.e. the membrane depolarization
induced by Ca2+-mediated activation of Sur1-Trpm4 channels
provides negative feedback that reduces the electrical driving
force for inward Ca2+ flux and thereby acts to protect the cell
from excessive Ca2+). However, sustained channel activity, as
can be brought about by severe ATP depletion, results in
continuous monovalent cation influx, converting an adaptive
advantage into a maladaptive phenomenon that leads to cy-
totoxic edema and necrotic (oncotic) cell death (16).
The potential benefits of Sur1-Trpm4 channel blockade
in stroke have been demonstrated in various studies. In a rat
model of MCAo stroke, Trpm4 gene suppression was asso-
ciated with preserved vascular integrity, enhanced angio-
genesis, reduced infarct volume, and improved functional
recovery (13). A study using primary cultures of human um-
bilical vein endothelial cells showed that suppression of
Trpm4 by pharmacologic inhibition or by small interfering
RNA protected cells against lipopolysaccharide-induced cell
death (26). Sulfonylurea therapy via low-dose glibenclamide
(a.k.a. glyburide), which binds to Sur1 and potently inhibits
the Sur1-Trpm4 channel, has been shown to confer protective
effects, including reduced edema, cortical stroke volume, and
overall mortality in various rodent stroke models (27Y29).
Moreover, sulfonylurea therapy in stroke patients with dia-
betes has been associated with improved neurologic function
and reduced rates of symptomatic hemorrhagic transformation
FIGURE 7. Oncosis and membrane blebbing in Sur1-positive/Trpm4-positive cells in acute cerebral infarcts. Note the cytoplasmic
vacuolization, membrane thickening, and irregularities present in endothelial cells of a small venule and a labeled neuron (A).
Intravascular IgG is present within Sur1-negative microvessels (B) but is extravasated around Sur1-positive endothelium in infarcts
(C). Similarly, intravascular IgG is present within Trpm4-negative microvessels (E) but is extravasated around Trpm4-positive
endothelium in infarcts (F). Quantitative evaluation of IgG labeling in infarcted and noninfarcted regions of interest (ROI) revealed
significant increases in perivascular IgG around Sur1-expressing and Trpm4-expressing versus nonexpressing vessels (D, G).
Channel expression in microvessels is also associated with early hemorrhagic transformation (H), perivascular TNF labeling (I), and
inflammation (J). ** p G 0.01. Original magnification: (A) 100; (B, C, E, F, HYJ) 40. Scale bar = 10 Km. Green/FITC, Trpm4, or
IgG; red/CY3, Sur1, IgG, or TNF or myeloperoxidase; DAPI, blue. Images shown are from Cases 3 and 6.
FIGURE 8. Pharmacologic inhibition of the Sur1-Trpm4 channel in a rat model of MCAo stroke mitigates TNF expression. Pen-
umbral cortex immunolabeled for TNF (left; red) and rat endothelial cell antigen 1 (RECA-1; middle; green) in rats treated with
vehicle (Veh) (A) or glibenclamide (Glib) (B). Merged images are shown to the right. Bar graph of quantitative regions of interest
(ROI) analysis is shown (C). * p G 0.05 (6 rats per group).
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and death relative to patients with diabetes who were man-
aged without sulfonylurea agents (30,31). In a pilot study,
stroke patients treated with RP-1127 (glyburide formulated
for intravenous infusion) showed improved clinical outcomes
compared with historical controls (30). The current study
further supports the hypothesis that Sur1 coassociates with
Trpm4 to form functional Sur1-Trpm4 channels in human
cerebral ischemia and suggests that channel expression is as-
sociated with postischemic blood-brain barrier disruption and
neuroinflammation. Because a constitutive function of this
channel has not been identified in normal brain and because
both Abcc8 and Trpm4 knockout mice exhibit near-normal
phenotypes, pharmacologic inhibition of the Sur1-Trpm4
channel may represent a promising novel therapeutic strate-
gy for patients sustaining focal cerebral infarction.
Because of an aging population, the absolute number of
stroke events is projected to increase in the next 2 decades
(32); thus, management of stroke patients remains a major
clinical challenge. Affected patients are at high risk for pro-
gressive neurologic deterioration and death caused by ma-
lignant cerebral edema. Although researchers have made
important progress in understanding the pathophysiology of
stroke in recent years, specific molecular mechanisms in-
volved in postischemic cell death remain relatively ill defined.
Elucidation of these mechanisms is necessary to optimize
outcomes for patients sustaining focal cerebral infarction. The
identification of new pharmacotherapies with extended thera-
peutic time windows remains a critical goal in medicine. The
current study is limited to examination of cerebral infarcts
originating from stroke patients with poor outcome (i.e.
death). Nonetheless, in light of recent data (14Y16,22,33Y35),
these data suggest an important role for the Sur1-Trpm4
channel in the pathophysiology of postischemic cell death and
implicates pharmacologic blockade of the Sur1-Trpm4 chan-
nel as a possible novel therapeutic strategy for mitigating
neuronal loss and malignant cerebral edema in patients sus-
taining large territorial cerebral infarction.
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